From Wikipedia, the free encyclopedia
Protein
This article needs to be updated . Please help update this article to reflect recent events or newly available information. (August 2021 )
Zonulin (haptoglobin 2 precursor)
[1] is a
protein that increases the permeability of
tight junctions between
cells of the wall of the
digestive tract .
[2] It was discovered in 2000 by
Alessio Fasano and his team at the
University of Maryland School of Medicine . As the mammalian analogue of zonula occludens toxin , secreted by
cholera pathogen
Vibrio cholerae , zonulin has been implicated in the pathogenesis of
coeliac disease and
diabetes mellitus type 1 .
[3]
Type 2 diabetic patients have shown increased zonulin.
[4]
Gliadin (a glycoprotein present in
gluten ) activates zonulin signaling irrespective of the genetic expression of autoimmunity, leading to increased
intestinal permeability of macromolecules.
[3]
[5]
Zonula occludens toxin is being studied as an adjuvant to improve absorption of drugs and vaccines.
[6] In 2014 a zonulin
receptor antagonist ,
larazotide acetate (formerly known as AT-1001), completed a
phase 2b clinical trial.
[7]
[8]
See also
References
^
UniProtKB - P00738 (HPT_HUMAN)
^ Vanuytsel, T; et al. (Dec 2013).
"The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease" . Tissue Barriers . 1 (5): e27321.
doi :
10.4161/tisb.27321 .
PMC
3943850 .
PMID
24868498 .
^
a
b Fasano, A (Jan 2011). "Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer". Physiol. Rev . 91 (1): 151–75.
CiteSeerX
10.1.1.653.3967 .
doi :
10.1152/physrev.00003.2008 .
PMID
21248165 .
^ Lopetuso LR, Scaldaferri F, Bruno G, Petito V, Franceschi F, Gasbarrini A (2015).
"The therapeutic management of gut barrier leaking: the emerging role for mucosal barrier protectors" . European Review for Medical and Pharmacological Sciences . 19 (6): 1068–1076.
PMID
25855934 .
^ Visser, Jeroen; Rozing, Jan; Sapone, Anna; Lammers, Karen; Fasano, Alessio (2009-05-01).
"Tight Junctions, Intestinal Permeability, and Autoimmunity Celiac Disease and Type 1 Diabetes Paradigms" . Annals of the New York Academy of Sciences . 1165 : 195–205.
doi :
10.1111/j.1749-6632.2009.04037.x .
ISSN
0077-8923 .
PMC
2886850 .
PMID
19538307 .
^ Lemmer, HJ; Hamman, JH (Jan 2013). "Paracellular drug absorption enhancement through tight junction modulation". Expert Opin Drug Deliv . 10 (1): 103–14.
doi :
10.1517/17425247.2013.745509 .
PMID
23163247 .
^
"Alba Therapeutics announces positive results of phase IIb trial in celiac disease" (Press release). Alba Therapeutics. February 11, 2014.
^ Leffler, DA; Kelly, CP; Green, PH; Fedorak, RN; DiMarino, A; Perrow, W; Rasmussen, H; Wang, C; Bercik, P; Bachir, NM; Murray, JA (June 2015).
"Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial" . Gastroenterology . 148 (7): 1311-9.e6.
doi :
10.1053/j.gastro.2015.02.008 .
PMC
4446229 .
PMID
25683116 .